2c5o
From Proteopedia
| Line 5: | Line 5: | ||
|SITE= <scene name='pdbsite=AC1:Ck2+Binding+Site+For+Chain+A'>AC1</scene> | |SITE= <scene name='pdbsite=AC1:Ck2+Binding+Site+For+Chain+A'>AC1</scene> | ||
|LIGAND= <scene name='pdbligand=CK2:4-(2,4-DIMETHYL-1,3-THIAZOL-5-YL)PYRIMIDIN-2-AMINE'>CK2</scene> | |LIGAND= <scene name='pdbligand=CK2:4-(2,4-DIMETHYL-1,3-THIAZOL-5-YL)PYRIMIDIN-2-AMINE'>CK2</scene> | ||
| - | |ACTIVITY= [http://en.wikipedia.org/wiki/ | + | |ACTIVITY= <span class='plainlinks'>[http://en.wikipedia.org/wiki/Non-specific_serine/threonine_protein_kinase Non-specific serine/threonine protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1 2.7.11.1] </span> |
|GENE= | |GENE= | ||
| + | |DOMAIN= | ||
| + | |RELATEDENTRY= | ||
| + | |RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2c5o FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2c5o OCA], [http://www.ebi.ac.uk/pdbsum/2c5o PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=2c5o RCSB]</span> | ||
}} | }} | ||
| Line 21: | Line 24: | ||
Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design., Kontopidis G, McInnes C, Pandalaneni SR, McNae I, Gibson D, Mezna M, Thomas M, Wood G, Wang S, Walkinshaw MD, Fischer PM, Chem Biol. 2006 Feb;13(2):201-11. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/16492568 16492568] | Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design., Kontopidis G, McInnes C, Pandalaneni SR, McNae I, Gibson D, Mezna M, Thomas M, Wood G, Wang S, Walkinshaw MD, Fischer PM, Chem Biol. 2006 Feb;13(2):201-11. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/16492568 16492568] | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
| + | [[Category: Non-specific serine/threonine protein kinase]] | ||
[[Category: Protein complex]] | [[Category: Protein complex]] | ||
| - | [[Category: Transferred entry: 2 7.11 1]] | ||
[[Category: Fischer, P M.]] | [[Category: Fischer, P M.]] | ||
[[Category: Gibson, D.]] | [[Category: Gibson, D.]] | ||
| Line 34: | Line 37: | ||
[[Category: Wang, S.]] | [[Category: Wang, S.]] | ||
[[Category: Wood, G.]] | [[Category: Wood, G.]] | ||
| - | [[Category: CK2]] | ||
[[Category: atp-binding]] | [[Category: atp-binding]] | ||
[[Category: cdk2]] | [[Category: cdk2]] | ||
| Line 49: | Line 51: | ||
[[Category: transferase]] | [[Category: transferase]] | ||
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Mar 31 02:16:43 2008'' |
Revision as of 23:16, 30 March 2008
| |||||||
| , resolution 2.10Å | |||||||
|---|---|---|---|---|---|---|---|
| Sites: | |||||||
| Ligands: | |||||||
| Activity: | Non-specific serine/threonine protein kinase, with EC number 2.7.11.1 | ||||||
| Resources: | FirstGlance, OCA, PDBsum, RCSB | ||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||
DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
Overview
The cyclin-dependent kinases (CDKs) have been characterized in complex with a variety of inhibitors, but the majority of structures solved are in the inactive form. We have solved the structures of six inhibitors in both the monomeric CDK2 and binary CDK2/cyclinA complexes and demonstrate that significant differences in ligand binding occur depending on the activation state. The binding mode of two ligands in particular varies substantially in active and inactive CDK2. Furthermore, energetic analysis of CDK2/cyclin/inhibitors demonstrates that a good correlation exists between the in vitro potency and the calculated energies of interaction, but no such relationship exists for CDK2/inhibitor structures. These results confirm that monomeric CDK2 ligand complexes do not fully reflect active conformations, revealing significant implications for inhibitor design while also suggesting that the monomeric CDK2 conformation can be selectively inhibited.
About this Structure
2C5O is a Protein complex structure of sequences from Homo sapiens. Full crystallographic information is available from OCA.
Reference
Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design., Kontopidis G, McInnes C, Pandalaneni SR, McNae I, Gibson D, Mezna M, Thomas M, Wood G, Wang S, Walkinshaw MD, Fischer PM, Chem Biol. 2006 Feb;13(2):201-11. PMID:16492568
Page seeded by OCA on Mon Mar 31 02:16:43 2008
Categories: Homo sapiens | Non-specific serine/threonine protein kinase | Protein complex | Fischer, P M. | Gibson, D. | Imcnae | Kontopidis, G. | Mcinnes, C. | Mezna, M. | Pandalaneni, S R. | Thomas, M. | Walkinshaw, M D. | Wang, S. | Wood, G. | Atp-binding | Cdk2 | Cell cycle | Cell division | Cyclin | Differential inhibition | Kinase | Mitosis | Nucleotide-binding | Phosphorylation | Polymorphism | Serine/threonine-protein | Transferase
